Review
Published on 02 Aug 2022
Immunotherapy in non-small cell lung cancer: Past, present, and future directions
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.877594
- 19,639 views
- 71 citations
10 articles related to "Anti Programmed Death 1"
Articles
Original Research
Published on 01 Feb 2022
The Effect of Inflammatory Markers on the Survival of Advanced Gastric Cancer Patients Who Underwent Anti-Programmed Death 1 Therapy
in Gastrointestinal Cancers: Gastric and Esophageal Cancers
Frontiers in Oncology
doi 10.3389/fonc.2022.783197
- 4,911 views
- 35 citations
Original Research
Published on 23 Mar 2023
Prognostic value of inflammatory markers and clinical features for survival in advanced or metastatic esophageal squamous cell carcinoma patients receiving anti-programmed death 1 treatment
in Gastrointestinal Cancers: Gastric and Esophageal Cancers
Frontiers in Oncology
doi 10.3389/fonc.2023.1144875
- 3,469 views
- 18 citations
Original Research
Published on 31 May 2024
Proteomic profiling and biomarker discovery for predicting the response to PD-1 inhibitor immunotherapy in gastric cancer patients
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1349459
- 4,704 views
- 8 citations
Case Report
Published on 14 Feb 2025
Case report: Long-term survival in synchronous double primary malignancies of lung adenocarcinomas and esophageal squamous cell carcinoma treated with definitive chemoradiotherapy and SBRT combined with anti-PD-1
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1548176
- 4,146 views
Case Report
Published on 16 Sep 2022
Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2022.984132
- 3,185 views
- 5 citations
Review
Published on 14 May 2019
Epstein-Barr Virus-Positive Natural Killer/T-Cell Lymphoma
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2019.00386
- 16,211 views
- 35 citations
Original Research
Published on 28 Feb 2023
Distribution of residual tumors in esophageal squamous cell carcinoma after neoadjuvant PD-1 blockade combined with chemotherapy
in Gastrointestinal Cancers: Gastric and Esophageal Cancers
Frontiers in Oncology
doi 10.3389/fonc.2023.1067897
- 3,242 views
- 2 citations
Clinical Trial
Published on 09 Sep 2022
Sintilimab maintenance therapy post first-line cytokine-induced killer cells plus chemotherapy for extensive-stage small cell lung cancer
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2022.852885
- 3,355 views
- 5 citations
Clinical Trial
Published on 26 Aug 2022
Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: A single-arm, open-label, phase II trial
in Gastrointestinal Cancers: Gastric and Esophageal Cancers
Frontiers in Oncology
doi 10.3389/fonc.2022.927781
- 6,100 views
- 47 citations